Functional and metabolomic analysis of urinary extracellular vesicles from juvenile mice with renal compensatory hypertrophy
This study suggests that uEVs contain bioactive components capable of inducing protective, anti-inflammatory, anti-fibrinolytic, and antioxidative effects in renal cells. These findings contribute to our understanding of uEVs' role in renal compensatory mechanisms after unilateral nephrectomy and may hold promise for future therapeutic interventions in renal diseases.PMID:38499276 | DOI:10.1016/j.bbadis.2024.167096 (Source: Biochimica et Biophysica Acta)
Source: Biochimica et Biophysica Acta - March 18, 2024 Category: Biochemistry Authors: Rasha Aly Sara Darwish Niharika Bala Areej Ebrahim Lawrence R Shoemaker Joel McCray Timothy J Garrett Abdel A Alli Source Type: research
Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment
AbstractAutosomal dominant polycystic kidney disease (ADPKD) is a major cause of end-stage kidney disease (ESKD). Vasopressin plays a pivotal role in ADPKD progression; therefore, the selective vasopressin V2 receptor antagonist tolvaptan is used as a key drug in the management of ADPKD. On the other hand, sodium –glucose cotransporter-2 inhibitors (SGLT2i), which may possibly stimulate vasopressin secretion due to the diuretic effect of the drug, have been shown to have both renal and cardioprotective effects in various populations, including those with non-diabetic chronic kidney disease. However, the ef fect of SGLT2i...
Source: CEN Case Reports - March 18, 2024 Category: Urology & Nephrology Source Type: research
Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)
This article reviews the role of SGLT2is in cardiac remodeling induced by different etiologies to provide a guideline for further evaluation of the mechanisms underlying the inhibition of pathological cardiac remodeling by SGLT2is, as well as the development of novel drug targets.PMID:38488029 | DOI:10.3892/mmr.2024.13197 (Source: Molecular Medicine)
Source: Molecular Medicine - March 15, 2024 Category: Molecular Biology Authors: Bixian Chen Jing Guo Hongmei Ye Xinyu Wang Yufei Feng Source Type: research
Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)
This article reviews the role of SGLT2is in cardiac remodeling induced by different etiologies to provide a guideline for further evaluation of the mechanisms underlying the inhibition of pathological cardiac remodeling by SGLT2is, as well as the development of novel drug targets.PMID:38488029 | DOI:10.3892/mmr.2024.13197 (Source: Molecular Medicine Reports)
Source: Molecular Medicine Reports - March 15, 2024 Category: Molecular Biology Authors: Bixian Chen Jing Guo Hongmei Ye Xinyu Wang Yufei Feng Source Type: research
Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)
This article reviews the role of SGLT2is in cardiac remodeling induced by different etiologies to provide a guideline for further evaluation of the mechanisms underlying the inhibition of pathological cardiac remodeling by SGLT2is, as well as the development of novel drug targets.PMID:38488029 | DOI:10.3892/mmr.2024.13197 (Source: Molecular Medicine)
Source: Molecular Medicine - March 15, 2024 Category: Molecular Biology Authors: Bixian Chen Jing Guo Hongmei Ye Xinyu Wang Yufei Feng Source Type: research
Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)
This article reviews the role of SGLT2is in cardiac remodeling induced by different etiologies to provide a guideline for further evaluation of the mechanisms underlying the inhibition of pathological cardiac remodeling by SGLT2is, as well as the development of novel drug targets.PMID:38488029 | DOI:10.3892/mmr.2024.13197 (Source: Molecular Medicine Reports)
Source: Molecular Medicine Reports - March 15, 2024 Category: Molecular Biology Authors: Bixian Chen Jing Guo Hongmei Ye Xinyu Wang Yufei Feng Source Type: research
Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)
This article reviews the role of SGLT2is in cardiac remodeling induced by different etiologies to provide a guideline for further evaluation of the mechanisms underlying the inhibition of pathological cardiac remodeling by SGLT2is, as well as the development of novel drug targets.PMID:38488029 | PMC:PMC10955520 | DOI:10.3892/mmr.2024.13197 (Source: Molecular Medicine Reports)
Source: Molecular Medicine Reports - March 15, 2024 Category: Molecular Biology Authors: Bixian Chen Jing Guo Hongmei Ye Xinyu Wang Yufei Feng Source Type: research
Cost-effectiveness of screening for chronic kidney disease using a cumulative eGFR-based statistic
ConclusionsCUSUMGFR-based screening policies for CKD are highly cost-effective in identifying patients at risk of end stage kidney disease in early stages of CKD. Given its simple requirement of a basic blood test, the CUSUMGFR-based screening can be easily incorporated into clinical workflow for disease monitoring and prevention. (Source: PLoS One)
Source: PLoS One - March 13, 2024 Category: Biomedical Science Authors: Reyhaneh Zafarnejad Source Type: research
Sodium –glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction
ConclusionsTreatment with SGLT2i influenced skeletal muscle pathology in patients with HFrEF and was associated with anti-atrophic, anti-inflammatory, and pro-metabolic effects. These changes may be regulatedvia IL-6 –kynurenine signalling. Together, clinical improvements following SGLT2i treatment in patients with HFrEF may be partly explained by their positive effects on skeletal muscle pathology. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - March 12, 2024 Category: Cardiology Authors: Nathanael Wood,
Sam Straw,
Chew W. Cheng,
Yu Hirata,
Marcelo G. Pereira,
Harrison Gallagher,
Stuart Egginton,
Wataru Ogawa,
Stephen B. Wheatcroft,
Klaus K. Witte,
Lee D. Roberts,
T. Scott Bowen Tags: Research Article Source Type: research
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Nature Reviews Rheumatology, Published online: 12 March 2024; doi:10.1038/s41584-024-01092-xGout is associated with various cardiometabolic–renal comorbidities that increase the risk of mortality. Sodium–glucose cotransporter type 2 (SGLT2) inhibitors show promise in both addressing the symptoms of gout and managing relevant comorbidities to help prevent premature mortality. (Source: Nature Reviews Rheumatology)
Source: Nature Reviews Rheumatology - March 12, 2024 Category: Rheumatology Authors: Chio Yokose Natalie McCormick Abhishek Abhishek Nicola Dalbeth Tristan Pascart Fr édéric Lioté Angelo Gaffo John FitzGerald Robert Terkeltaub Meghan E. Sise James L. Januzzi Deborah J. Wexler Hyon K. Choi Source Type: research
LESSONS LEARNED from EARLY-STAGE CLINICAL TRIALS for DIABETIC NEPHROPATHY
Expert Opin Investig Drugs. 2024 Mar 11. doi: 10.1080/13543784.2024.2326025. Online ahead of print.ABSTRACTINTRODUCTION: The evolution of treatment for diabetic nephropathy illustrates how basic biochemistry and physiology have led to new agents such as SGLT2 inhibitors and mineralocorticoid blockers. Conversely, clinical studies performed with these agents have suggested new concepts for investigational drug development. We reviewed currently available treatments for diabetic nephropathy and then analyzed early clinical trials of new agents to assess potential for future treatment modalities.AREAS COVERED: We searched Cli...
Source: Expert Opinion on Investigational Drugs - March 11, 2024 Category: Drugs & Pharmacology Authors: Marc Rendell Source Type: research
SGLT2 inhibitors vs. GLP-1 receptor agonists and clinical outcomes in patients with diabetes with/without atrial fibrillation
CONCLUSION: Considering the high risk of developing HF and/or high prevalence of concomitant HF in patients with diabetes, whether SGLT2i should be the preferred treatment to GLP-1RA for such a high-risk population requires further investigation.PMID:38466894 | DOI:10.1210/clinem/dgae157 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - March 11, 2024 Category: Endocrinology Authors: Yi-Hsin Chan Tze-Fan Chao Shao-Wei Chen Hsin-Fu Lee Pei-Ru Li Yung-Hsin Yeh Chi-Tai Kuo Lai-Chu See Gregory Y H Lip Source Type: research
